Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
about
Optimal management of seizures associated with tuberous sclerosis complex: current and emerging optionsRapamycin and its analogues (rapalogs) for tuberous sclerosis complexSubependymal Giant Cell Astrocytoma (SEGA) Treatment UpdateThe tuberous sclerosis complexNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyThe TSC1-TSC2 complex: a molecular switchboard controlling cell growthAberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomasRapamycin and rapalogs for tuberous sclerosis complexNeuroimaging in pediatric phakomatoses. An educational review.Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysisThe neurology of mTORAmino acids and mTORC1: from lysosomes to diseasePathological and molecular advances in pediatric low-grade astrocytomaStochastic model of Tsc1 lesions in mouse brainTherapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)Rapamycin attenuates the progression of tau pathology in P301S tau transgenic miceInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerPrenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 miceHereditary genodermatoses with cancer predispositionRapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorderRapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficitsMechanism-based treatment in tuberous sclerosis complex.Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.Clinical presentation and diagnosis of tuberous sclerosis complex in infancy.Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population.Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycinRapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical modelsPediatric low-grade gliomas and the need for new options for therapy: Why and how?Effects of Rapamycin on Clinical Manifestations and Blood Lipid Parameters in Different Preeclampsia-like Mouse ModelsCuring epilepsy: progress and future directionsSubependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report.The PIK3CA gene as a mutated target for cancer therapy.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumorsmTORC1 activation in childhood ependymoma and response to sirolimus.From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.
P2860
Q22305852-602E7D23-8379-4C9E-9A0A-C1E7360C3E62Q24194140-5E8D5AB7-52E3-45A0-85F5-9FCEAF4EA501Q24597688-C149508B-0651-4779-B23B-AAB8BE67EBC1Q24628011-EF3946DF-3417-44CA-ABE6-437A801B547EQ24628724-1446E372-7616-42C7-A54B-E4AD9FD31298Q24645204-4E3D01F0-32DE-4E7D-BD43-5A64B55EB0A5Q24658269-0013C8B0-ED5E-45B9-85F5-DA37175B72F2Q26471128-5C45A73C-7307-4205-8493-F0AE38F3379FQ26752705-78604AB4-9FEE-44D7-AA87-C971AC6FCEF4Q26799757-04FAB785-F536-4F02-B5D5-30D02CE96393Q26824286-A5744E9F-7DA5-4229-81FC-55EA3B0D0D07Q27009377-B06ECA69-3A18-434D-A247-3E76DA2371E5Q27026123-F6D1E9CE-8799-4E90-9B5E-A36C3B39D1B5Q27319406-6099701B-0D9D-44A2-A9AA-4F22D03B2A11Q28481010-DA08FB0E-C133-43C4-AB88-25151EF74764Q28487708-342281D1-9EE8-4E01-9F2A-5C27089C6377Q29618030-90F3F3B8-A487-4561-B700-1EE849E80DEFQ30444988-19E18F21-CDAD-4916-B16A-2B380B87655CQ30470596-7D1BB6F8-92D8-4075-845C-CBD67EE96AF5Q30541746-03CAE3E8-E186-46E7-B241-2AB186931980Q30573030-673035CC-FB69-4DF4-AA25-E5C26C497B5DQ30597707-570DE165-85FD-425D-BED9-2BEB3F8A2F2AQ30746587-9A106F91-AB28-4D45-9AE3-E93DA8C4AE97Q31140724-C2493B63-0746-4409-B648-2FE9B36270F3Q31144575-CF3B4CC1-6FFB-4DEA-BED7-952AD2C40880Q33274047-8ED869DA-8300-445F-B1BB-34F3240EFAB7Q33305157-E29B03D5-92B4-49D5-8C58-6C42F438EBEEQ33316872-7B3200A6-1148-4990-9E70-D0B7A91D0939Q33403043-CA526C93-507A-438F-96A3-BCF36AD1F01FQ33430534-7E0641F2-8820-45AD-9ED8-0C18859A729BQ33607387-808AC7B8-CCC7-4B3C-A9D8-886781834DC7Q33646644-B815055C-9085-4122-AAC0-2FBAE9DC67A6Q33655266-8F3EA653-4A2C-45D9-9412-A04D0364A9CBQ33694246-591AB50A-A3BC-4563-9493-2A8FAB2F0CCFQ33699378-E9B71329-7F71-4E7D-9E45-C63A3133AF4AQ33711691-950F5DC9-2777-4BC2-AEFF-51B2ABAFA1C6Q33746501-750977D3-68CA-49E0-879F-F5452DCE7EAFQ33750454-47DFF2E0-DE67-4686-AF21-991A94C46282Q33757948-FFF54B3A-7666-42B1-BB33-919972E71A99Q33805859-D729A49F-F8D4-4745-BB7B-E92E0CFC0D77
P2860
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@ast
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@en
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@nl
type
label
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@ast
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@en
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@nl
prefLabel
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@ast
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@en
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@nl
P2093
P3181
P356
P1433
P1476
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
@en
P2093
Argirios Dinopoulos
Cynthia Tudor
David Neal Franz
Gail Chuck
Gopalan Sethuraman
Jennifer Leonard
Kerry R Crone
Marguerite Care
P304
P3181
P356
10.1002/ANA.20784
P407
P577
2006-03-01T00:00:00Z